Revvity stock
RVTYNYSERevvity, Inc., HealthcareISIN US7140461093
56Score 56 out of 100, Neutral
Price and trend
82 / 100
Price history
+68% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 39% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 4.5% below its 52-week high. Largest decline in 20 years: 63% (October 2007 to March 2009).
Chart figures for advanced users
- SMA 50$149.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$113.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$82.26
- The lowest closing price of the last twelve months.
- Resistance$165.78
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Revvity, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $17.66B, is number 15 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.86B (up 3.7% year on year) and earnings of $241.68M (down 18.3%).
- For fiscal 2026, analysts expect on average revenue of $2.87B (up 0.3%) and adjusted earnings per share of $5.42 (up 7%).
Show more
- MEQIRI Score 56 out of 100 (Neutral): rank 329 of 714 in Healthcare, median 53.
- The P/E is 69.3 (Medical (Diagnostics & Research) median 33.7, own median of recent years 36.4).
- Our model puts fair value at $93.07, with the price 70% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 43 years.
- Earnings turn into cashFree cash flow 234% of earnings over the last 12 months.Fundamentals 77
Weaknesses
- Above fair valuePrice 70% above the fair value of $93.07.Valuation 21
- Richly valuedP/E 69.3, Medical (Diagnostics & Research) median 33.7, own median 36.4.Valuation 21
- Earnings per share fallingDown 20.4% a year since 2020.Growth 20
Its standout strengths are momentum and technical analysis, while valuation and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $66.48 and expensive above $155.12 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $109.09 (cash-flow model) and $77.05 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $84.72, at 8.7% it would be $104.90.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 4 Oct 2026, revenue rose 4.6% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 1.4% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 53%, operating 12%, net 8%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 1 Feb 2027in 81 days
- Last reported
- 3 Nov 2026EPS reported $1.38 (expected $1.30)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.42+1.3%
- Revenue
- $2.87B+0.5%
- Earnings per share
- $5.96+1.1%
- Revenue
- $3.03B+0.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −0.3%Guidance raised: organic growth of 4% to 5% (previously 3% to 4%), adjusted EPS of $5.30 to $5.40, up $0.10.
“Consequently, we are now expecting total company organic growth this year of 4% to 5%, up from our prior 3% to 4% outlook.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.29M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Gonzales AnitaSale
1 Oct 2026, VP and CAO
- Shares
- 84
- Price
- $155.48
- Value
- $13,060
- Krakowiak MaxwellSale
21 Sept 2026, Please See Remarks
- Shares
- 1,631
- Price
- $144.53
- Value
- $235,728
- Vohra Tajinder SSale
16 Sept 2026, Please See Remarks
- Shares
- 7,330
- Price
- $140.88
- Value
- $1.03M
Show 1 more
- Gonzales AnitaSale
20 Jul 2026, Vice President and CAO
- Shares
- 85
- Price
- $109.48
- Value
- $9,306
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Revvity
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 56
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Labcorp HoldingsLH $30.23B64
- Quest DiagnosticsDGX $28.55B69
- Guardant HealthGH $20.94B45
- Medpace HoldingsMEDP $18.59B83
- Eurofins ScientificERF.PA $17B61
- Charles River Laboratories InternationalCRL $16.42B55
- ICON PublicICLR $14.96B62
- bioMérieuxBIM.PA $12.07B70
ETFs that hold Revvity
Held by 35 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 1.64% | 0.40% | €1.49B |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.26% | 0.49% | €318.39M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.26% | 0.15% | €3.27B |
Show 5 more
| Xtrackers S&P 500 Equal Weight UCITS ETF 1CXDEW | 0.25% | 0.15% | €14.88B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.25% | 0.15% | €592.11M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.23% | 0.30% | €944.34M |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.20% | 0.39% | €188.08M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.16% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 28 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 19 Jun 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.